RU2006105716A - Производные пиридазина и их применение в качестве терапевтических средств - Google Patents
Производные пиридазина и их применение в качестве терапевтических средств Download PDFInfo
- Publication number
- RU2006105716A RU2006105716A RU2006105716/04A RU2006105716A RU2006105716A RU 2006105716 A RU2006105716 A RU 2006105716A RU 2006105716/04 A RU2006105716/04 A RU 2006105716/04A RU 2006105716 A RU2006105716 A RU 2006105716A RU 2006105716 A RU2006105716 A RU 2006105716A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- hydrogen
- compound
- cycloalkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000004892 pyridazines Chemical class 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 46
- 201000010099 disease Diseases 0.000 claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 10
- 241000124008 Mammalia Species 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 45
- 239000001257 hydrogen Substances 0.000 claims 45
- 125000003710 aryl alkyl group Chemical group 0.000 claims 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 125000005843 halogen group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 20
- -1 chloro, methyl Chemical group 0.000 claims 18
- 125000004122 cyclic group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 14
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 9
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 4
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000000651 prodrug Chemical class 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- NBJCNSIBRAFHCZ-UHFFFAOYSA-N CCC(C1=CC=C(N(CC2)CCN2C(C2=C(C(F)(F)F)C=CC=C2)=O)N=N1)S(N)(=O)=O Chemical compound CCC(C1=CC=C(N(CC2)CCN2C(C2=C(C(F)(F)F)C=CC=C2)=O)N=N1)S(N)(=O)=O NBJCNSIBRAFHCZ-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- XPFRFMOQDWFKID-UHFFFAOYSA-N [4-[6-(2-cyclopropylethoxy)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(OCCC3CC3)=CC=2)CC1 XPFRFMOQDWFKID-UHFFFAOYSA-N 0.000 claims 1
- HZYJFYDBOVZGIW-UHFFFAOYSA-N [4-[6-(2-phenylethoxy)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(OCCC=3C=CC=CC=3)=CC=2)CC1 HZYJFYDBOVZGIW-UHFFFAOYSA-N 0.000 claims 1
- WBLYCICMFISNEP-UHFFFAOYSA-N [4-[6-(2-phenylethylamino)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(NCCC=3C=CC=CC=3)=CC=2)CC1 WBLYCICMFISNEP-UHFFFAOYSA-N 0.000 claims 1
- KIMDQFVNARRKRG-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfanyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(SCCC=3C=CC=CC=3)=CC=2)CC1 KIMDQFVNARRKRG-UHFFFAOYSA-N 0.000 claims 1
- KOTQLIKJTDTRGO-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfinyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(=CC=2)S(=O)CCC=2C=CC=CC=2)CC1 KOTQLIKJTDTRGO-UHFFFAOYSA-N 0.000 claims 1
- SLRFPPGXCUIOEE-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfonyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(=CC=2)S(=O)(=O)CCC=2C=CC=CC=2)CC1 SLRFPPGXCUIOEE-UHFFFAOYSA-N 0.000 claims 1
- ACASVUBSIKGUOX-UHFFFAOYSA-N [4-[6-(3-methylbutylsulfanyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound N1=NC(SCCC(C)C)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 ACASVUBSIKGUOX-UHFFFAOYSA-N 0.000 claims 1
- XTRLGWKVRHBAFP-UHFFFAOYSA-N [4-[6-[methyl(2-phenylethyl)amino]pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound C=1C=C(N2CCN(CC2)C(=O)C=2C(=CC=CC=2)C(F)(F)F)N=NC=1N(C)CCC1=CC=CC=C1 XTRLGWKVRHBAFP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49111603P | 2003-07-30 | 2003-07-30 | |
| US49109503P | 2003-07-30 | 2003-07-30 | |
| US60/491,116 | 2003-07-30 | ||
| US60/491,095 | 2003-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006105716A true RU2006105716A (ru) | 2007-09-10 |
Family
ID=34118852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006105716/04A RU2006105716A (ru) | 2003-07-30 | 2004-07-29 | Производные пиридазина и их применение в качестве терапевтических средств |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7514436B2 (https=) |
| EP (2) | EP2316826A1 (https=) |
| JP (1) | JP4831577B2 (https=) |
| KR (1) | KR20060037410A (https=) |
| CN (1) | CN101712653A (https=) |
| AT (1) | ATE555789T1 (https=) |
| AU (1) | AU2004261249B2 (https=) |
| BR (1) | BRPI0412343A (https=) |
| CA (1) | CA2533897A1 (https=) |
| EC (1) | ECSP066315A (https=) |
| ES (1) | ES2386353T3 (https=) |
| IL (1) | IL173032A0 (https=) |
| MA (1) | MA28009A1 (https=) |
| NO (1) | NO20060974L (https=) |
| RU (1) | RU2006105716A (https=) |
| SG (1) | SG145699A1 (https=) |
| TN (1) | TNSN06032A1 (https=) |
| WO (1) | WO2005011653A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| SI1867644T1 (sl) * | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1648874B1 (en) * | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| CN101712653A (zh) * | 2003-07-30 | 2010-05-26 | 泽农医药公司 | 哒嗪衍生物和它们作为治疗剂的用途 |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| CA2580762A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| AR051091A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| MX2007005205A (es) | 2004-10-29 | 2007-05-11 | Kalypsys Inc | Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma. |
| WO2006095822A1 (ja) * | 2005-03-11 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | スルホンアミド化合物およびその医薬 |
| WO2006125194A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| JP2009501733A (ja) * | 2005-07-20 | 2009-01-22 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物 |
| EP1940815B1 (en) | 2005-10-25 | 2018-08-15 | Kalypsys, Inc. | Salts of modulators of ppar and methods of treating metabolic disorders |
| EP1966183A4 (en) * | 2005-12-20 | 2010-12-29 | Merck Frosst Canada Ltd | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE |
| WO2007136746A2 (en) * | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
| WO2007143597A2 (en) | 2006-06-05 | 2007-12-13 | Novartis Ag | Organic compounds |
| EP2032566A4 (en) * | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| US20080182851A1 (en) * | 2006-11-20 | 2008-07-31 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
| TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| DK2142529T3 (da) * | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| CA2750564A1 (en) | 2009-02-17 | 2010-08-26 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| EP2459568A4 (en) | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE |
| FR2948939B1 (fr) * | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| HRP20170507T1 (hr) | 2011-06-22 | 2017-06-02 | Purdue Pharma Lp | Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| BR112014029365A2 (pt) | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | inibidores seletivos de células indiferenciadas |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| CA2977817A1 (en) * | 2015-03-04 | 2016-09-09 | Children's Hospital Medical Center | Methods for treating cancer |
| AU2017281907B2 (en) | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| KR102728619B1 (ko) | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| EP3731859B1 (en) | 2017-12-27 | 2025-08-20 | St. Jude Children's Research Hospital, Inc. | Pyridazine compounds for use to treat disorders associated with castor |
| CN111868055B (zh) * | 2018-02-16 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Trpc6的抑制剂 |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| CA3188340A1 (en) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985657A (en) * | 1959-10-12 | 1961-05-23 | Paul A J Janssen | 1-(aroylalkyl)-4-heterocyclylpiperazines |
| ATE3294T1 (de) | 1978-10-02 | 1983-05-15 | Gruppo Lepetit S.P.A. | 6-aminosubstituierte n-pyrrolyl-3-pyridazinamine, deren herstellung und sie enthaltende pharmazeutische antihypertensive zusammensetzungen. |
| ZM1785A1 (en) * | 1984-03-26 | 1986-03-27 | Janssen Pharmaceutica Nv | Anti-virally active phyridazinamines |
| US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
| ES8802151A1 (es) * | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
| US5106973A (en) * | 1987-11-23 | 1992-04-21 | Janssen Pharmaceutica N.V. | Pyridzainamine derivatives |
| MY104343A (en) * | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
| US5166147A (en) * | 1990-07-09 | 1992-11-24 | The Du Pont Merck Pharmaceutical Company | 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JPH107572A (ja) * | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| US5976497A (en) * | 1997-08-04 | 1999-11-02 | Resolution Pharmaceuticals, Inc. | Dopamine D4 receptor ligands |
| AU8096798A (en) * | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| US7160878B2 (en) * | 2000-07-27 | 2007-01-09 | Eli Lilly And Company | Substituted heterocyclic amides |
| US7232662B2 (en) | 2000-09-26 | 2007-06-19 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5 |
| KR20040010713A (ko) | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| ES2306859T3 (es) * | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| OA12793A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
| DE60326436D1 (en) * | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| MXPA04010555A (es) * | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2004203871A (ja) * | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| GB0303439D0 (en) * | 2003-02-14 | 2003-03-19 | Pfizer Ltd | Antiparasitic terpene alkaloids |
| EP1648874B1 (en) * | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| CN101712653A (zh) * | 2003-07-30 | 2010-05-26 | 泽农医药公司 | 哒嗪衍生物和它们作为治疗剂的用途 |
| US20050119252A1 (en) * | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| EP1781293A1 (en) * | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
-
2004
- 2004-07-29 CN CN200910224929A patent/CN101712653A/zh active Pending
- 2004-07-29 JP JP2006522072A patent/JP4831577B2/ja not_active Expired - Fee Related
- 2004-07-29 EP EP10184440A patent/EP2316826A1/en not_active Withdrawn
- 2004-07-29 EP EP04779555A patent/EP1651616B1/en not_active Expired - Lifetime
- 2004-07-29 US US10/566,856 patent/US7514436B2/en not_active Expired - Fee Related
- 2004-07-29 WO PCT/US2004/024541 patent/WO2005011653A2/en not_active Ceased
- 2004-07-29 RU RU2006105716/04A patent/RU2006105716A/ru not_active Application Discontinuation
- 2004-07-29 CA CA002533897A patent/CA2533897A1/en not_active Abandoned
- 2004-07-29 BR BRPI0412343-3A patent/BRPI0412343A/pt not_active IP Right Cessation
- 2004-07-29 ES ES04779555T patent/ES2386353T3/es not_active Expired - Lifetime
- 2004-07-29 AU AU2004261249A patent/AU2004261249B2/en not_active Ceased
- 2004-07-29 AT AT04779555T patent/ATE555789T1/de active
- 2004-07-29 KR KR1020067002006A patent/KR20060037410A/ko not_active Ceased
- 2004-07-29 SG SG200805678-0A patent/SG145699A1/en unknown
-
2006
- 2006-01-09 IL IL173032A patent/IL173032A0/en unknown
- 2006-01-25 EC EC2006006315A patent/ECSP066315A/es unknown
- 2006-01-27 TN TNP2006000032A patent/TNSN06032A1/en unknown
- 2006-02-27 MA MA28837A patent/MA28009A1/fr unknown
- 2006-02-28 NO NO20060974A patent/NO20060974L/no not_active Application Discontinuation
-
2009
- 2009-02-20 US US12/390,117 patent/US8148378B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005011653A2 (en) | 2005-02-10 |
| KR20060037410A (ko) | 2006-05-03 |
| NO20060974L (no) | 2006-04-27 |
| EP2316826A1 (en) | 2011-05-04 |
| ECSP066315A (es) | 2006-07-28 |
| AU2004261249B2 (en) | 2008-09-04 |
| CA2533897A1 (en) | 2005-02-10 |
| US7514436B2 (en) | 2009-04-07 |
| AU2004261249A1 (en) | 2005-02-10 |
| EP1651616A2 (en) | 2006-05-03 |
| US8148378B2 (en) | 2012-04-03 |
| SG145699A1 (en) | 2008-09-29 |
| CN101712653A (zh) | 2010-05-26 |
| TNSN06032A1 (en) | 2007-10-03 |
| WO2005011653A3 (en) | 2005-04-14 |
| JP2007500715A (ja) | 2007-01-18 |
| IL173032A0 (en) | 2006-06-11 |
| EP1651616B1 (en) | 2012-05-02 |
| ES2386353T3 (es) | 2012-08-17 |
| US20060205713A1 (en) | 2006-09-14 |
| BRPI0412343A (pt) | 2006-09-05 |
| MA28009A1 (fr) | 2006-07-03 |
| ATE555789T1 (de) | 2012-05-15 |
| JP4831577B2 (ja) | 2011-12-07 |
| US20090197890A1 (en) | 2009-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| ES2375134T3 (es) | Derivados de piperazina y su uso como agentes terapéuticos. | |
| ES2359840T5 (es) | Derivados de piridina para inhibición de estearoil-CoA-desaturasa humana | |
| JP5043668B2 (ja) | 複素環誘導体および治療薬としてのそれらの使用 | |
| EP1804799B1 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| ES2380020T3 (es) | Derivados de nicotinamida y su uso como agentes terapéuticos | |
| RU2009139915A (ru) | Производные имидазолидинона | |
| MX2007009592A (es) | Terapia de combinacion. | |
| CN101083986A (zh) | 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途 | |
| CN104379597A (zh) | 改善膈肌功能的方法 | |
| JP2007500715A5 (https=) | ||
| CA2597069A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| JP2013014623A (ja) | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| CN101084207A (zh) | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 | |
| JP2008513504A5 (https=) | ||
| RU2004113207A (ru) | Хинолиновые производные в качестве антагонистов нейропептида y | |
| JP2008513515A5 (https=) | ||
| AU2012345557A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| JP2012180377A (ja) | 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用 | |
| WO2007044085A2 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| JP2005508923A5 (https=) | ||
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| CN115427042A (zh) | 组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080828 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20080924 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20080924 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20080924 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090408 |